These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 37821927

  • 1. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
    Pirintr P, Saengklub N, Boonpala P, Hamlin RL, Kijtawornrat A.
    BMC Vet Res; 2023 Oct 12; 19(1):201. PubMed ID: 37821927
    [Abstract] [Full Text] [Related]

  • 2. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Häggström J, Borgarelli M.
    Aust Vet J; 2016 Sep 12; 94(9):324-8. PubMed ID: 27569835
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, Küchenhof H, Glaus T.
    J Vet Intern Med; 2020 Nov 12; 34(6):2232-2241. PubMed ID: 32945575
    [Abstract] [Full Text] [Related]

  • 5. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
    Pirintr P, Saengklub N, Limprasutr V, Sawangkoon S, Kijtawornrat A.
    J Vet Med Sci; 2017 Sep 12; 79(9):1480-1488. PubMed ID: 28717064
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK, DeFrancesco TC, Meurs KM, Papich MG.
    J Vet Intern Med; 2023 Sep 12; 37(6):2003-2010. PubMed ID: 37776546
    [Abstract] [Full Text] [Related]

  • 8. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Sep 12; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 9. Decreased sympathetic tone after short-term treatment with enalapril in dogs with mild chronic mitral valve disease.
    Chompoosan C, Buranakarl C, Chaiyabutr N, Chansaisakorn W.
    Res Vet Sci; 2014 Apr 12; 96(2):347-54. PubMed ID: 24559801
    [Abstract] [Full Text] [Related]

  • 10. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Apr 12; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 11. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov 12; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 12. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
    Franchini A, Borgarelli M, Abbott JA, Menciotti G, Crosara S, Häggström J, Lahmers S, Rosenthal S, Tyrrell W.
    J Vet Cardiol; 2022 Jun 12; 41():99-120. PubMed ID: 35316716
    [Abstract] [Full Text] [Related]

  • 13. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F, Neves J, Maddox TW, Hodgkiss-Geere HM, Bode EF, Dukes-McEwan J.
    Open Vet J; 2020 Jan 12; 9(4):375-383. PubMed ID: 32042661
    [Abstract] [Full Text] [Related]

  • 14. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
    Sabetti MC, Fidanzio F, Troìa R, Perissinotto L, Romito G, Mazzoldi C, Quintavalla C, Crosara S, Dondi F.
    J Vet Cardiol; 2022 Jun 12; 41():57-69. PubMed ID: 35245876
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2018 Jan 12; 32(1):72-85. PubMed ID: 29214723
    [Abstract] [Full Text] [Related]

  • 16. Holter monitoring of small breed dogs with advanced myxomatous mitral valve disease with and without a history of syncope.
    Rasmussen CE, Falk T, Domanjko Petrič A, Schaldemose M, Zois NE, Moesgaard SG, Ablad B, Nilsen HY, Ljungvall I, Höglund K, Häggström J, Pedersen HD, Bland JM, Olsen LH.
    J Vet Intern Med; 2014 Jan 12; 28(2):363-70. PubMed ID: 24417236
    [Abstract] [Full Text] [Related]

  • 17. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE, Falk T, Zois NE, Moesgaard SG, Häggström J, Pedersen HD, Ablad B, Nilsen HY, Olsen LH.
    J Vet Intern Med; 2012 Jan 12; 26(1):76-84. PubMed ID: 22151356
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
    Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, Kaltsatos V.
    J Vet Intern Med; 2010 Jan 12; 24(2):331-41. PubMed ID: 20102506
    [Abstract] [Full Text] [Related]

  • 19. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
    Kim HJ, Kim J, Kim S, Kim HJ.
    BMC Vet Res; 2023 Mar 07; 19(1):59. PubMed ID: 36882760
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ, French AT, Van Israël N, Smith SG, Swift ST, Lee AJ, Corcoran BM, Dukes-McEwan J.
    J Small Anim Pract; 2005 Mar 07; 46(3):121-30. PubMed ID: 15789807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.